Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:EU EMA/INS/GCP/126568/2023 - Annual Report of the Good Clinical Practice (GCP) Inspectors' Working Group (IWG) 2022 2023 3.1.2 - Randomisation

From GxPlex

Revision as of 19:36, 27 June 2026 by gxplex>GxPlexBot (Import from GxPlex Excel)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search


Document Information

Document information
Reference EU EMA/INS/GCP/126568/2023

- Annual Report of the Good Clinical Practice (GCP) Inspectors' Working Group (IWG) 2022 2023

Validity area EU
Scope(s) G
Document name EMA/INS/GCP/126568/2023

- Annual Report of the Good Clinical Practice (GCP) Inspectors' Working Group (IWG) 2022

Version / Revision 2023
Status Current
Document type Official guideline
Language(s) EN
Description EMA/INS/GCP/164938/2024

Inspections Office Quality and Safety of Medicines Department

Annual Report of the Good Clinical Practice (GCP) Inspectors' Working Group (IWG) 2023 Adopted by the GCP IWG on 26 November 2024

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details

Scope G
Document part 3.1.2 - Randomisation
Language EN
Original entry by Florian Adragna
Contributors
Tags (EN)
Tags (original language)
Tags (FR)
Comment Examples of critical and major findings (randomisation)

Text

Examples of critical and major findings in the sub-categories of the three main categories "General", "Trial Management", and "Investigational Site" are listed below. [...] Randomisation/Blinding/Codes IMP: • Accidental Suspected Unexpected Serious Adverse Reaction (SUSAR) unmasking: there were three cases where unblinding information was included in SUSAR queries / acknowledgement reports that were sent to blinded sponsor personnel and in two cases the unblinding information was subsequently forwarded to investigator sites. • Deficiencies in maintaining the integrity of the blind. • An issue in the Interactive Response Technology (IRT) system was not solved during the study. No possibility of changes in the IRT system were planned at least in the agreement with the vendor in case of issues. Only a simple communication to investigators was undertaken. [...]